Reversing Artery Plaque: 8 Supplements Ranked by the Evidence | Simon Hill, MSc

What It Covers

Simon Hill reviews eight supplements ranked by human trial evidence for reversing arterial plaque, covering EPA, aged garlic extract, vitamin K2, niacin, CoQ10, berberine, nattokinase, and pomegranate extract. He evaluates imaging studies and cardiovascular outcome trials to determine which supplements genuinely regress atherosclerosis versus which improve biomarkers without delivering measurable arterial benefit.

Key Questions Answered

• •Pure EPA dosing: Icosapent ethyl at 4 grams daily reduced total coronary plaque volume by 9% and dangerous low-attenuation plaque by 17% over 18 months in the EVAPORATE trial, while the placebo group's plaque grew 11%. These benefits occurred independently of LDL changes in statin-treated patients, confirming EPA works through anti-inflammatory and plaque-stabilizing mechanisms beyond cholesterol lowering alone.
• •EPA form matters critically: Standard fish oil combining EPA and DHA does not replicate the plaque regression seen with pure EPA. A meta-analysis of 10 RCTs found DHA may compete with EPA for cell membrane incorporation, blunting its arterial benefits. For patients with established cardiovascular disease, elevated triglycerides, and statin therapy, only prescription icosapent ethyl — not over-the-counter fish oil — matches the REDUCE-IT trial profile showing 25% fewer major cardiovascular events.
• •Aged garlic extract targets vulnerable plaque: At 2,400mg daily for 12 months, aged garlic extract produced statistically significant reductions in low-attenuation plaque — the lipid-rich, rupture-prone type — in two separate RCTs involving metabolic syndrome and diabetic populations. A third independent European trial showed participants were nearly three times more likely to experience slower coronary calcification progression, plus an 8mmHg systolic blood pressure reduction comparable to some antihypertensive medications.
• •Biomarker trap — niacin warning: High-dose niacin raises HDL by 17% and lowers triglycerides, yet two trials — NIA Plaque MRI and AIM-HIGH — showed zero additional plaque regression or cardiovascular event reduction when added to statin therapy. AIM-HIGH was stopped early for futility. This illustrates that improving a surrogate marker like HDL does not automatically translate to arterial benefit, a pattern also seen with CETP inhibitors and confirmed by Mendelian randomization data.
• •Nattokinase evidence gap: A large Chinese observational study reported 36% average carotid plaque reduction at 10,800 fibrinolytic units daily, but the only rigorous double-blind RCT — the NAPPS trial with 265 participants over three years — found zero effect on carotid atherosclerosis progression at standard doses. Blood pressure data from multiple RCTs does show a consistent 3.5mmHg systolic reduction at 2,000 FUs daily, making that the only currently supported cardiovascular application.
• •Vitamin K2 slows calcification selectively: At 720mcg of MK-7 form combined with 1,000 IU vitamin D3 daily for 24 months, vitamin K2 did not reverse existing calcified plaque but meaningfully slowed progression in participants with coronary artery calcium scores above 400. A meta-analysis of 14 trials confirmed an average 17-unit reduction in calcification progression. Whether slower calcification reduces cardiovascular events remains untested — the ongoing DANCODE trial is designed to answer this directly.